

# **Certificate of Analysis**

This material is a research-grade material prepared by custom synthesis. The quantity available is limited, and this limits the extent and type of analytical data which can be obtained. This Certificate is presented in descriptive format for use by analytical chemists who are trained in the use of research-grade materials. Research materials often contain higher levels of residual solvents and/or water, and we urge you to use the corrected purity where needed rather than the raw HPLC purity.

BDG Synthesis certifies that this reference material meets or exceeds the specifications stated in this data sheet.

Barry Dent

Barry R. Dent, PhD, Director

18 January 2007

Name: Lansoprazole-d<sub>4</sub>

**CAS Number:** none (103577-45-3 unlabelled)

**Structure:** 

 $C_{16}H_{10}D_4F_3N_3O_2S = 373.39$ **Molecular Weight:** 

Lot Number: BDG 6631.1

White, crystalline solid **Appearance:** 

**Purity by HPLC:** 97.9 %

**Isotopic Purity:** Under 0.5 % d<sub>0</sub>

**Expiry Date:** 18 January 2012

> This expiry date is assigned from experience gained with the material in the laboratory and/or on storage. It is not possible to perform formal storage stability studies because of the small amount of material

available.

#### **Storage and Handling:**

Temperature: refrigerate for prolonged storage; may be handled and shipped at ambient temperature. Humidity: not believed to be hygroscopic; may be handled in normal laboratory atmosphere.

Light: store in an amber vial and protect from bright light.

Caution: Only experienced laboratory personnel should handle the material.

1/5

• Custom synthesis of analytical reference standards, metabolites, stable isotope labelled compounds

**BDG Synthesis** 

Gracefield Research Centre, Building F. Gracefield Road, Lower Hutt, New Zealand. Phone: + 64 4 569 0520 Fax: + 64 4 569 0521

info@bdg.co.nz www.bdg.co.nz

#### **Identity and Purity:**

#### **Source of Material**

The material was made by an unambiguous synthetic route, using literature procedures where possible; starting materials were purchased from reputable sources and all intermediates were checked for identity by NMR.

### **Proton NMR Spectrum**

Identity: the signals are consistent with the proposed structure and in accord with literature where available. Isotopic labelling: signals at the sites of deuteration are greatly diminished, compared with what would be expected for unlabelled material, indicating clean deuteration.

Residual solvents: no residual solvents are observed.

Impurities: an unidentified impurity at approximately 2 % w/w is present, based on a doublet at 8.05 ppm.

#### **Carbon-13 NMR Spectrum**


Identity: the signals are consistent with the proposed structure and in accord with literature where available. Isotopic labelling: signals at the sites of deuteration have collapsed to small multiplets compared with what would be expected for unlabelled material, indicating clean deuteration.


**High-resolution mass spectrum (FAB+):** found m/z 374.1077.  $C_{16}H_{11}D_4F_3N_3O_2S$  [M+H]<sup>+</sup> requires m/z 374.1088. The deviation of 2.9 ppm is within normally accepted limits for the establishment of identity by HRMS. No signal for  $d_0$  material was seen (detection limit about 0.5 %).


**HPLC:** A sharp, symmetrical peak is observed (97.9 area %). Note: in the absence of reference materials for preparing calibration curves, it is assumed that all peaks have the same detector response. Where possible, the conditions of analysis follow a pharmacopeial or literature method, or have been adapted from same.

**Elemental Analysis:** Found: C 51.51, H 2.79, D 2.23, N 11.15 % C<sub>16</sub>H<sub>10</sub>D<sub>4</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>S requires: C 51.46, H 2.70, D 2.16, N 11.26 %

The elemental analyses fall within generally accepted limits for establishing the molecular formula given. The results may also be taken to imply the absence of significant quantities of water or inorganic salts (which have not been elsewhere tested for because of sample size limitations).








## BDG - Analysis of Lansoprazole-d4

Column : Phenomenex Luna C18(2) 5um 250 x 4.6 mm Guard : Phenomenex Security Guard C18 RP 4 x 3 mm Mobile Phase : 64:36 10mM Na2HPO4 pH=7.6 : Acetonitrile

Flow Rate: 1.0 mL/min Sample Solvent: Mobile Phase Column Temperature: 20C Injection Volume: 10 uL Detection: UV at 280 nm

Sample Name	BDG 6631.1	Instrument	AnalyticalLC01
Acquisition	19/11/2006, 13:33:08	Method (rev.)	LC10110a (2)
Sequence	BDG_19Nov2006b	Vial Position	1
Operator	solvation010\cerityadmin	Injection	1 of 1



#### **Area Percent Report**

Peak#	RT	Peak Height	Peak Area	Width	Area %
1	3.42 min	2.2425	14.3452	0.0946 min	0.071 %
2	11.07 min	28.0294	408.7081	0.2261 min	2.018 %
3	13.14 min	1197.2415	19828.6570	0.2572 min	97.911 %